Swog Cancer Research Network

This study tested whether adding cetuximab (an antibody) to afatinib (a targeted pill) helps people with advanced EGFR-mutant lung cancer live longer. 174 patients were randomly assigned to receive either the combination or afatinib alone. The results showed no significant improv…

This study tested adding elotuzumab to a standard three-drug combination (bortezomib, lenalidomide, dexamethasone) for people newly diagnosed with high-risk multiple myeloma, a blood cancer that tends to come back quickly. The goal was to find the safest dose of elotuzumab and se…

This study tested two different treatments for people newly diagnosed with a slow-growing type of lymphoma (follicular non-Hodgkin's lymphoma). Both treatments combined standard chemotherapy (CHOP) with a targeted antibody — either rituximab or a radioactive antibody called tosit…

This phase II trial tested two different drug combinations in 240 people with advanced HER2-positive colorectal cancer that had spread and could not be removed by surgery. One group received the antibodies trastuzumab and pertuzumab, while the other received cetuximab (an antibod…

This phase III trial tested whether adding nab-paclitaxel to the standard two-drug chemo (gemcitabine and cisplatin) helps people with newly diagnosed, advanced biliary tract cancers live longer. Over 450 patients took part. The goal is to see if the three-drug combo improves ove…

This study tested whether adding the drug TAK-700 to standard hormone therapy helps men with newly diagnosed prostate cancer that has spread live longer than adding the drug bicalutamide. Over 1,300 men took part. The goal was to see which combination works better for controlling…

This study tested whether adding the drug ramucirumab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced thymic cancer that cannot be removed by surgery or has spread. Twenty-one participants were randomly assigned to receive chemo with or without ra…

This phase 3 trial tested whether the drug everolimus could prevent kidney cancer from coming back after surgery. Over 1,500 patients with high-risk kidney cancer took either everolimus or a placebo daily for 54 weeks. The study found a small improvement in recurrence-free surviv…

This phase II trial tested the drug isatuximab in 43 patients with AL amyloidosis that had come back or stopped responding to treatment. Isatuximab is a monoclonal antibody that may help stop abnormal protein buildup. The study measured how well the drug reduced disease markers a…